Document is current
Any future updates will be listed below
-
Authors
Hoek, Danique W. Bos-van den
van de Water, Loïs F.
Vos, Pieter G.
Hoedjes, Meeke
Roodbeen, Ruud
Klarenbeek, Bastiaan R.
Geijsen, Debby
Smets, Ellen M. A.
van Laarhoven, Hanneke W. M.
Henselmans, Inge
- License Information
-
More Information
Article History
Received: 16 July 2024
Accepted: 29 August 2024
First Online: 20 September 2024
Declarations
:
: This study was performed in line with the principles of the Declaration of Helsinki. Approval for the CHOICE trial was granted by the Ethics Committee of Amsterdam Medical Center, University of Amsterdam, on August 11, 2015 (2015_149). The Ethics Committee of Amsterdam Medical Center, University of Amsterdam, provided an exemption for seeking ethics approval for the SYMPHONY study on June 6, 2019 (W19_203), and for the SOURCE trial on March 18, 2019 (W19_094).
: Informed consent was obtained from all individual participants included in the study.
: Danique Bos-van den Hoek, Lois van de Water, Pieter Vos, Meeke Hoedjes, Ruud Roodbeen, Bastiaan Klarenbeek, Debby Geijsen, Ellen Smets and Inge Henselmans declare they have no financial interests. Hanneke van Laarhoven has received research funding and/or medication supply from Amphera, Anocca, Astellas, AstraZeneca, Beigene, Boehringer, Daiichy-Sankyo, Dragonfly, MSD, Myeloid, ORCA, Servier; has had a consultant/advisory role for Auristone, Incyte, Merck, Myeloid, Servier; and was a speaker for Astellas, Beigene, Benecke, BMS, Daiichy-Sankyo, JAAP, Medtalks, Novartis, Springer, Travel Congress Management B.V.
